Reimagining Antibody Manufacturing

It is important to efficiently manufacture biopharmaceutical products once commercialized to maximize profit margins. Many companies choose to manufacture mammalian cell culture-derived products using fed-batch technology. However, continuous manufacturing is more efficient than fed-batch manufacturing at the same production scale.

Learn more about FUJIFILM Diosynth Biotechnologies' new MaruX manufacturing platform, which is designed to improve the efficiency and quality of antibody manufacturing. The platform uses single-use bioreactors run in perfusion and a fully single-use connected downstream process, allowing for improved product quality, especially for unstable products.

This article also reviews five key factors to consider when choosing continuous bioprocessing.